Pat Reilly had good reason to worry about Alzheimer’s disease: Her mother had it and she saw firsthand the havoc it could wreak on a family, much of it financial.
So Reilly, 77, a retired social worker in Ann Arbor, Michigan, applied for a long-term care insurance policy. Wary of enrolling people at risk for dementia, the insurance company tested her memory three times before issuing the policy.
However, Reilly knew something the insurer did not: She has inherited the ApoE4 gene, which increases the lifetime risk of developing Alzheimer’s.
“I decided I’d best get long-term care insurance,” she said.
About 5.5 million people in the US have Alzheimer’s disease and they constitute half of all nursing home residents. Yet very few people in the country have been tested for the ApoE4 gene.
However, last month, with the approval of the US Food and Drug Administration, the gene testing company 23andMe began offering tests that reveal whether people have the variant, as well as assessing their risks for developing such conditions as Parkinson’s and celiac disease.
Other genetics companies are planning to offer similar tests and soon millions of people will have a better idea of what their medical futures might be. Research has found that many, like Reilly, are likely to begin preparing for the worst.
However, for companies selling long-term care insurance, the tests could be a disaster, sending risky patients in search of policies even as those with fewer risks shy away, damaging an already fragile business.
“There is a question about whether the industry is in a death spiral anyway,” Consumer Federation of America director of insurance Robert Hunter said. “This could make it worse.”
The tests are simple: All people have to do is send away a saliva sample and pay US$199. Their disease risks, if they say they want to know them, will be delivered with a report on ancestry and on how their genes influence such traits as flushing when they drink alcohol or having straight hair.
The company does not reveal how many people have received disease-risk data, but it says that in Britain and Canada, where it has offered such testing for several years, about three-quarters of their customers have asked for it.
23andMe has sold its genetic services to more than 2 million people worldwide since 2007.
The issue for now is with long-term care insurance, not employment and not — at least so far — health insurance.
Under the Genetic Information Nondiscrimination Privacy Act, companies cannot ask employees to take gene tests and cannot use any such results in employment decisions; insurers are not permitted to require gene tests or to use the results in coverage decisions.
However, legislation proposed in the US House of Representatives would exempt corporate “wellness” programs from some of these requirements and the American Health Care Act, passed by the House, would permit US states to waive some insurance safeguards regarding pre-existing conditions.
Companies selling long-term care insurance — unlike medical insurers — are permitted to ask about health status and take future health into consideration when deciding whom to insure and how much to charge.
The 23andMe test results do not appear in people’s medical records and the company promises not to disclose identifiable findings to third parties.
It is up to the customers to reveal them — and the fear for insurers is that many will not.
Two-thirds of nursing home residents are on Medicaid, and the remaining private insurers are already struggling.
In the early 2000s, more than 100 firms offered long-term care insurance, according to the US Department of the Treasury. By the end of 2015, only 12 firms offered it and new enrollees fell from 171,000 to 104,000.
The insurers charged too little for the policies, experts say; policyholders have turned out to be much sicker than anticipated.
To pay for an unanticipated increase in policyholders who develop Alzheimer’s, insurers would have to raise prices, said Don Taylor, a professor of public policy at Duke University who has studied the issue.
Increasing numbers of people at low risk might decide the insurance was not worth the rising price. Even many at high risk would eventually find the policies unaffordable. It is the definition of an insurance death spiral.
If that happens, even more people with Alzheimer’s will end up on Medicaid, with the federal government paying for their nursing home care, said Mark Rothstein, director of the bioethics institute at the University of Louisville’s medical school.
Someone must pay, he said.
For 23andMe, the new tests are simply a way to help people learn about their genetic makeup.
“People clearly want information about themselves,” 23andMe chief executive Anne Wojcicki said. “There is a demand.”
Yet even if just a minority of 23andMe customers decided to game the insurance system, “it’s enough to perturb the market,” said Robert Cook-Deegan, a professor at the School for the Future of Innovation in Society at Arizona State University, who has studied the issue.
DECOUPLING? In a sign of deeper US-China technology decoupling, Apple has held initial talks about using Baidu’s generative AI technology in its iPhones, the Wall Street Journal said China has introduced guidelines to phase out US microprocessors from Intel Corp and Advanced Micro Devices Inc (AMD) from government PCs and servers, the Financial Times reported yesterday. The procurement guidance also seeks to sideline Microsoft Corp’s Windows operating system and foreign-made database software in favor of domestic options, the report said. Chinese officials have begun following the guidelines, which were unveiled in December last year, the report said. They order government agencies above the township level to include criteria requiring “safe and reliable” processors and operating systems when making purchases, the newspaper said. The US has been aiming to boost domestic semiconductor
Nvidia Corp earned its US$2.2 trillion market cap by producing artificial intelligence (AI) chips that have become the lifeblood powering the new era of generative AI developers from start-ups to Microsoft Corp, OpenAI and Google parent Alphabet Inc. Almost as important to its hardware is the company’s nearly 20 years’ worth of computer code, which helps make competition with the company nearly impossible. More than 4 million global developers rely on Nvidia’s CUDA software platform to build AI and other apps. Now a coalition of tech companies that includes Qualcomm Inc, Google and Intel Corp plans to loosen Nvidia’s chokehold by going
ENERGY IMPACT: The electricity rate hike is expected to add about NT$4 billion to TSMC’s electricity bill a year and cut its annual earnings per share by about NT$0.154 Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) has left its long-term gross margin target unchanged despite the government deciding on Friday to raise electricity rates. One of the heaviest power consuming manufacturers in Taiwan, TSMC said it always respects the government’s energy policy and would continue to operate its fabs by making efforts in energy conservation. The chipmaker said it has left a long-term goal of more than 53 percent in gross margin unchanged. The Ministry of Economic Affairs concluded a power rate evaluation meeting on Friday, announcing electricity tariffs would go up by 11 percent on average to about NT$3.4518 per kilowatt-hour (kWh)
OPENING ADDRESS: The CEO is to give a speech on the future of high-performance computing and artificial intelligence at the trade show’s opening on June 3, TAITRA said Advanced Micro Devices Inc (AMD) chairperson and chief executive officer Lisa Su (蘇姿丰) is to deliver the opening keynote speech at Computex Taipei this year, the event’s organizer said in a statement yesterday. Su is to give a speech on the future of high-performance computing (HPC) in the artificial intelligence (AI) era to open Computex, one of the world’s largest computer and technology trade events, at 9:30am on June 3, the Taiwan External Trade Development Council (TAITRA) said. Su is to explore how AMD and the company’s strategic technology partners are pushing the limits of AI and HPC, from data centers to